Fulgent Genetics Agrees to Acquire Bako Diagnostics and ...

Fulgent Genetics Expands Pathology Footprint With $55.5 Million Acquisition of Bako Diagnostics and StrataDx - Channelchek

Fulgent Genetics is accelerating its transformation into a comprehensive precision diagnostics platform with the announced acquisition of selected assets of Bako Diagnostics and the full acquisition of StrataDx in a combined transaction valued at approximately $55.5 million. The deal, which will be funded entirely with cash on hand, is expected to close in the first half of 2026, subject to customary regulatory approvals. The acquisition marks a…

Fulgent Genetics to Acquire Bako Diagnostics and StrataDx

EL MONTE, Calif.–(BUSINESS WIRE)–Fulgent Genetics, Inc. (NASDAQ: FLGT), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics, a premier pathology laboratory headquartered in Alpharetta, GA and to acquire StrataDx, a premier dermatopathology laboratory located in Lexingto…

Fulgent Genetics Agrees to Acquire Bako Diagnostics and ...